Advertisement

Search Results

Advertisement



Your search for The ASCO ,The ASCO matches 20907 pages

Showing 1 - 50


solid tumors

Vimseltinib Approved by the FDA for Symptomatic TGCT

The U.S. Food and Drug Administration (FDA) has approved vimseltinib (Romvimza), a kinase inhibitor, for adults with symptomatic tenosynovial giant cell tumor (TGCT) for which surgical resection will potentially cause worsening functional limitation or severe morbidity. MOTION Trial Efficacy was...

lung cancer
cardio-oncology
issues in oncology

Comprehensive CT Scans May Help to Identify Atherosclerosis Among Patients With Lung Cancer

Several cardiovascular risk factors such as advanced age and smoking history may be prevalent among patients with lung cancer at the time of diagnosis and may increase their risk of future cardiovascular disease, according to findings presented by Malozzi et al at the American College of...

immunotherapy
issues in oncology
solid tumors

Are Immune Checkpoint Inhibitors Effective in Hospitalized Patients With Cancer?

Immune checkpoint inhibitors may be ineffective among patients hospitalized with cancer, according to a recent study published by Riaz et al in JCO Oncology Practice. Background Immune checkpoint inhibitors have transformed treatment for many cancer types but are often restricted for inpatient use...

gynecologic cancers
immunotherapy
issues in oncology

Flagellin and Immune Checkpoint Inhibition in Patients With Ovarian Cancer

The interference of gut bacteria could explain the ineffectiveness of immune checkpoint therapy in some patients with ovarian cancer, according to a recent study published by McGinty et al in Cancer Immunology Research.  Background There are over 10,000 ovarian cancer–related deaths in the United...

colorectal cancer
issues in oncology

Colorectal Cancer Treatment Resistance: Oncofetal Reprogramming

Researchers may have uncovered a major factor contributing to treatment resistance in patients with colorectal cancer, according to a recent study published by Mzoughi et al in Nature Genetics. Background Colorectal cancer is one of the deadliest cancer types across the world, with treatment...

colorectal cancer
issues in oncology

Potential Benefit of Consuming Yogurt in Decreasing the Risk of Certain Types of Colorectal Cancers

Long-term yogurt intake may protect against the development of colorectal cancer through changes in the gut microbiome, according to a recent study published by Ugai et al in Gut Microbes. Background Yogurt—which contains live strains of bacteria—is thought to protect against many types of...

pancreatic cancer
issues in oncology

Novel Blood Test May Help to Identify Pancreatic Ductal Adenocarcinoma at an Earlier Stage

A novel blood test may aid physicians in the earlier detection of pancreatic ductal adenocarcinoma and potentially improve survival rates for the disease, according to a recent study published by Montoya et al in Science Translational Medicine. Background Pancreatic ductal adenocarcinoma is the...

prostate cancer

Final Overall Survival Results From TALAPRO-2 in Unselected Patients With Metastatic Castration-Resistant Prostate Cancer

The final overall survival results from cohort 1 of the phase III TALAPRO-2 trial showed a statistically significant and clinically meaningful improvement with the PARP inhibitor talazoparib plus the androgen receptor inhibitor enzalutamide vs standard-of-care enzalutamide in treatment-naive...

prostate cancer

Nicholas D. James, PhD, FRCP, MBBS, on an ADT Option: Transdermal Estradiol Patches

Nicholas D. James, PhD, FRCP, MBBS, of The Institute of Cancer Research and The Royal Marsden Hospital NHS Foundation Trust, discusses findings from an embedded phase II randomized study from the STAMPEDE trial. The study assessed the efficacy and toxicity of transdermal estradiol patches vs...

Talazoparib Plus Enzalutamide Significantly Improves Overall Survival in Prostate Cancer Regardless of HRR Gene Status

Studies show that about one-quarter of advanced prostate cancers have alterations in DNA damage response genes involved directly or indirectly in homologous recombination repair (HRR) gene alterations, including BRCA1/BRCA2 genes, which can sensitize them to treatment with PARP inhibitors. Final...

prostate cancer
supportive care

Benjamin Maughan, MD, PharmD, on Exercise Therapy for Patients With Advanced Prostate Cancer

Benjamin Maughan, MD, PharmD, of Huntsman Cancer Institute, discusses the effects of a 12-week, structured, guided exercise program called Personal Optimism With Exercise Recovery (POWER) on fatigue and peak aerobic exercise capacity in patients with advanced prostate cancer receiving...

colorectal cancer

Triplet Regimen Demonstrates Benefit in BRAF V600E–Mutant Metastatic Colorectal Cancer

The BRAF inhibitor encorafenib plus the monoclonal antibody cetuximab combined with mFOLFOX (modified folinic acid, fluorouracil, and oxaliplatin) significantly improved overall response in BRAF V600E–mutant metastatic colorectal cancer, according to data presented at the 2025 ASCO Gastrointestinal ...

palliative care
lung cancer

How Telehealth Is Broadening Access to Early Palliative Care and Improving Outcomes for Patients With Advanced Lung Cancer

Although national guidelines, including ASCO’s palliative care guideline,1 call for the early integration of palliative and oncology care for patients with advanced cancer, only 36% of those with a very poor prognosis and 18% of those with a poor prognosis receive palliative care services.2 The...

lymphoma

Primary Analysis of ZUMA-2: Bruton Tyrosine Kinase Inhibitor–Naive Relapsed or Refractory Mantle Cell Lymphoma

ZUMA-2 is a single-arm, multicenter, open-label phase II study that investigated leukapheresed adults with mantle cell lymphoma whose disease was refractory to or had relapsed after up to five prior lines of therapy, including anthracycline or bendamustine-containing chemotherapy; anti-CD20...

global cancer care
issues in oncology
solid tumors

WHO, St. Jude Launch New Global Platform to Deliver Cancer Drugs to Pediatric Patients in Low-, Middle-Income Countries

The World Health Organization (WHO) and St. Jude Children’s Research Hospital have begun distributing critical cancer drugs to pediatric patients in two of six pilot countries through the new Global Platform for Access to Childhood Cancer Medicines. Background Every year, about 400,000 children...

lymphoma

FDA Approves Brentuximab Vedotin With Lenalidomide and Rituximab for Relapsed or Refractory LBCL

The U.S. Food and Drug Administration (FDA) has approved brentuximab vedotin (Adcetris) in combination with lenalidomide and a rituximab product for adult patients with relapsed or refractory large B-cell lymphoma (LBCL)—including diffuse large B-cell lymphoma (DLBCL) not otherwise specified, DLBCL ...

hematologic malignancies
issues in oncology

Does Epstein-Barr Virus Increase Cancer Risk Among Kidney Transplant Recipients?

Kidney transplantation using donor organs carrying the Epstein-Barr virus may increase the risk of posttransplant lymphoproliferative disorder among recipients who have never been exposed to the virus, according to a recent study published by Potluri et al in the Annals of Internal Medicine....

gynecologic cancers
issues in oncology

Short- vs Standard-Course Radiation Therapy for Endometrial Cancer

Short-course, higher-dose vaginal brachytherapy for endometrial cancer may demonstrate comparable efficacy to more frequent, lower-dose sessions, according to a recent study published by Suneja et al in JCO Oncology Advances. Background Endometrial cancer is the most common cancer type of the...

colorectal cancer

Experimental Regimen Demonstrates Benefit in BRAF V600E–Mutant Metastatic Colorectal Cancer

The BRAF inhibitor encorafenib plus the monoclonal antibody cetuximab combined with mFOLFOX (modified folinic acid, fluorouracil, and oxaliplatin) significantly improved overall response in BRAF V600E–mutant metastatic colorectal cancer, according to data presented at the 2025 ASCO Gastrointestinal ...

solid tumors

FDA Approves Mirdametinib for Neurofibromatosis Type 1

On February 11, the U.S. Food and Drug Administration approved mirdametinib (Gomekli), a kinase inhibitor, for adult and pediatric patients aged 2 years and older with neurofibromatosis type 1 (NF1) who have symptomatic plexiform neurofibromas (PN) not amenable to complete resection. ReNeu Trial...

colorectal cancer

Dual Immunotherapy Extended Progression-Free Survival in Metastatic Colorectal Cancer Subgroup

An immunotherapy combination for advanced, highly mutated colorectal cancer has significantly delayed disease progression vs single-agent therapy, according to data presented at the 2025 ASCO Gastrointestinal Cancers Symposium.1 The phase III CheckMate 8HW trial compared the PD-1 inhibitor...

prostate cancer
issues in oncology

Mobile Prostate Cancer Screening Clinic Was Effective in Detecting Prostate Cancer in Underserved Men

Globally, prostate cancer is the second most frequently diagnosed cancer and the fifth-leading cause of cancer-related death among men—and the leading cause of cancer-related death in Central America and sub-Saharan Africa. Four years ago, British researchers launched the “Man Van” pilot mobile...

issues in oncology

Survey Finds More Than Half of Oncologists Are Experiencing Professional Burnout

In JCO Oncology Advances, Schenkel et al published the results of an ASCO survey measuring professional well-being, satisfaction, and the effect of both on career plans among oncologists in the United States. The analysis revealed a higher rate of burnout compared with that observed a decade ago....

survivorship
issues in oncology
solid tumors

Pain May Influence Use of Nonopioid Substances Among Cancer Survivors

Experiencing pain may increase the risk that cancer survivors will use cigarettes and cannabis, according to a recent study published by Powers et al in Cancer. Background Pain and the use of cigarettes, e-cigarettes, alcohol, and cannabis commonly occur together in the general population. Cancer...

solid tumors
issues in oncology
immunotherapy
colorectal cancer
hepatobiliary cancer
gastrointestinal cancer

Anticancer Drug Pharmacokinetics May Differ by Sex

Investigators may have uncovered notable pharmacokinetic differences between male and female patients in at least 14 anticancer drugs, according to a recent study published by Delahousse et al in ESMO Open. Background Many cancer drugs have a narrow therapeutic window. As a result, slight...

multiple myeloma
myelodysplastic syndromes
leukemia

In Case You Missed It: Additional Studies of Interest From ASH 2024

A record-breaking number of abstracts were submitted for the 2024 American Society of Hematology (ASH) Annual Meeting & Exposition, and nearly 8,000 were accepted. The ASCO Post strives to provide in-depth coverage of those with the greatest impact. Here, we offer snapshots of others of...

solid tumors
issues in oncology
breast cancer
colorectal cancer
gynecologic cancers
lung cancer
hepatobiliary cancer

Trends in Cancer Incidence and Mortality in Appalachia

Investigators have found that although fewer patients may be diagnosed with and dying from cancer in Appalachia, cancer incidence and mortality rates remain substantially higher compared with elsewhere in the United States, according to a recent study published by Burus et al in the Journal of the...

solid tumors
issues in oncology
immunotherapy

Using AI to Identify Treatment Options for Castleman Disease

A novel artificial intelligence (AI) tool uncovered an effective treatment for a patient with idiopathic multicentric Castleman’s disease, according to a recent study published by Mumau et al in The New England Journal of Medicine. Background Idiopathic multicentric Castleman’s disease is a rare...

kidney cancer
issues in oncology
immunotherapy

Novel Personalized Cancer Vaccine May Be Effective in Patients With Stage III and IV Clear Cell Renal Cell Carcinoma

Patients with stage III or IV clear cell renal cell carcinoma may have achieved a successful anticancer immune response following initiation of a novel personalized cancer vaccine, according to a recent study published by Braun et al in Nature. Background The standard treatment for stage III or IV...

skin cancer
genomics/genetics
issues in oncology

New Study Identifies Potential Genes Implicated in Treatment-Resistant Melanoma

Researchers have found that inhibiting the S6K2 gene could be an effective strategy for managing treatment-resistant melanoma, according to a recent study published by Lipchick et al in Science Translational Medicine. Background Cases of melanoma—the deadliest type of skin cancer—are currently...

leukemia
myelodysplastic syndromes

FDA Approves Preparative Regimen for Allogeneic HSCT in Patients With AML or MDS

On January 21, the U.S. Food and Drug Administration (FDA) approved treosulfan (Grafapex), an alkylating agent, with fludarabine as a preparative regimen for allogeneic hematopoietic stem cell transplantation (HSCT) in adult and pediatric patients 1 year of age and older with acute myeloid leukemia ...

thyroid cancer

Is Thyroid Cancer Overdiagnosed?

A retrospective study provides new evidence that thyroid cancer continues to be overdiagnosed and that aggressive screening and treatment of thyroid cancer has not led to higher survival rates. The research was published by Chen et al in The Lancet Diabetes & Endocrinology. “Many studies have...

myelodysplastic syndromes

Is Clonal Cytopenia of Undetermined Significance Distinct From Lower-Risk Myelodysplastic Syndrome?

High-risk patients with clonal cytopenia of undetermined significance have very similar characteristics and outcomes as patients with lower-risk myelodysplastic syndrome (MDS), which can be informative with regard to prognosis, management, and clinical trial eligibility, said Zhuoer (Zoey) Xie, MD, ...

immunotherapy
issues in oncology
hematologic malignancies

CAR T-Cell Therapy Not Linked to Secondary Cancers, Study Finds

Researchers have found no evidence that chimeric antigen receptor (CAR) T-cell therapy caused secondary cancers in the modified T cells, according to a recent study published by Jadlowsky et al in Nature Medicine. Background CAR T-cell therapy is a personalized type of immunotherapy that employs...

prostate cancer

Potential Link Between Early Side Effects From Radiation Therapy and Long-Term Side Effects in Patients With Prostate Cancer

The risk of developing more serious long-term urinary and bowel health issues may be higher in men undergoing radiation therapy for prostate cancer who experience side effects early in treatment, according to a recent study published by Nikitas et al in The Lancet Oncology. The findings highlighted ...

colorectal cancer

Results From FIRE-4 Show Liquid Biopsy Can Detect RAS/BRAF-Mutated Metastatic Colorectal Cancer

The results from the phase III FIRE-4 randomized clinical trial show that liquid biopsy accurately identified patients with RAS/BRAF V600E wild type–mutated metastatic colorectal cancer. The findings confirm the high clinical relevance of liquid biopsy performed at baseline before the start of...

issues in oncology

AI May Boost Efficacy of Cancer Care, but Physicians Remain Critical to Decision-Making, Study Finds

Although artificial intelligence (AI)-assisted radiotherapy may help physicians make more informed decisions when treating patients with cancer, there may be challenges in how physicians work with the technology, according to a recent study published by Niraula et al in Nature Communications. Study ...

breast cancer
immunotherapy

Neoadjuvant Radiotherapy May Hamper Immunotherapy Response in Patients With Breast Cancer

Researchers have provided novel insights into the effects of radiation on the immune cells surrounding breast cancer tumors, according to a recent study published by Yoneyama et al in the International Journal of Radiation Oncology • Biology • Physics. The findings revealed that the relationship...

breast cancer

FDA Approves First Companion Diagnostic to Identify Patients With Metastatic Breast Cancer Eligible for T-DXd

The U.S. Food and Drug Administration (FDA) has approved a label expansion for the PATHWAY anti-HER2/neu (4B5) Rabbit Monoclonal Primary Antibody to identify patients with hormone receptor (HR)-positive, HER2-ultralow metastatic breast cancer who may be eligible for treatment with fam-trastuzumab...

lymphoma

Can R-CHOP–Like Therapy Effectively Treat Late-Relapse DLBCL?

Late relapse of diffuse large B-cell lymphoma (DLBCL) may represent a new lymphoma arising from a common precursor cell that is essentially chemotherapy-naive. Treatment with curative intent using a second-line regimen like R-CHOP (rituximab cyclophosphamide, doxorubicin, prednisone, and...

lung cancer
genomics/genetics
issues in oncology

Predicting Response to KRAS G12C Inhibitors in NSCLC

Researchers may have uncovered a novel strategy to help predict how well patients with KRAS G12C–mutated non–small cell lung cancer (NSCLC) will respond to new therapies, according to a recent study published by Kato et al in Clinical Cancer Research. Study Methods and Results Researchers developed ...

prostate cancer
issues in oncology

Rising Advanced Prostate Cancer Rates in California Follow Changes to Recommendations

The incidence of advanced prostate cancer rose and the mortality rate plateaued in most regions across the state of California following the decision to cease routinely screening all men for the disease, according to a recent study published by Van Blarigan et al in JAMA Network Open. The findings...

leukemia

Novel BTK and BCL2 Inhibitors Redefine CLL Treatment Across Front-Line and Relapsed Settings

Two pivotal phase III trials presented at the 2024 American Society of Hematology (ASH) Annual Meeting & Exposition mark a significant shift toward chemotherapy-free approaches in chronic lymphocytic leukemia (CLL), offering potentially more effective and tolerable treatment options for both...

issues in oncology
global cancer care
pain management

Chemotherapy Linked to Chronic Neuropathy for 4 in Every 10 Patients: Global Analysis Results

Worldwide, cancer chemotherapy is linked to chronic painful neuropathy for around 4 in every 10 patients treated with these drugs, suggests a pooled data analysis of the available evidence published by D’Souza et al in Regional Anesthesia & Pain Medicine. Notwithstanding wide regional...

solid tumors
breast cancer
issues in oncology

Cancer Symptoms Mistaken for Pregnancy Symptoms Could Lead to Delays in Cancer Diagnosis

Misdiagnosing cancer symptoms as normal pregnancy-related changes among pregnant individuals could lead to delays in treatment, according to a recent study published by Marcu et al in the British Journal of General Practice. Study Methods and Results In the study, researchers recruited 20 women...

gynecologic cancers
issues in oncology

Salpingectomy During Other Abdominal Surgeries May Lower Ovarian Cancer Risk

Fallopian tube removal performed during other abdominal surgeries could reduce the risk of ovarian cancer incidence among women who have already completed their families, according to a recent study published by Kather et al in PLOS Medicine. Background Ovarian cancer is the third most common...

gynecologic cancers
genomics/genetics

Hereditary Ovarian Cancer Risk: Unlocking New Insights

Researchers have uncovered new heredity genes that may contribute to an increased risk of developing high-grade serous ovarian cancer, according to a recent study published by Subramanian et al in npj Genomic Medicine. Background High-grade serous ovarian cancer is one of the most prevalent and...

cns cancers
breast cancer
issues in oncology

Does Brain MRI Surveillance Benefit Asymptomatic Patients With Stage IV Breast Cancer?

Researchers have found that asymptomatic brain metastases may be more common in patients with stage IV breast cancer than previously understood, according to a recent study published by Ahmed et al in Neuro-Oncology. The findings suggest that physicians may need to reconsider current screening...

breast cancer

CheckMate 7FL: Neoadjuvant Immunochemotherapy in ER-Positive, HER2-Negative Breast Cancer

A phase III trial has shown adding the PD-1 inhibitor nivolumab to anthracycline- and taxane-based chemotherapy that patients receive ahead of surgery may improve breast cancer cure rates. CheckMate-7FL involved 510 patients with estrogen receptor (ER)-positive, HER2-negative early breast cancer,...

solid tumors

Expediting Cancer Diagnoses With Acoustofluidics?

A novel system using standing surface acoustic waves may effectively and precisely separate circulating tumor cells from red blood cells, according to a novel study published by Kouhkord and Naserifar in the Physics of Fluids. Background Cancer accounted for nearly 10 million deaths in 2020—nearly...

Advertisement

Advertisement




Advertisement